{"ticker": {"uuid": "fe00bf31-60d2-47cd-98f8-6374f89063c2", "symbol": "CNTA", "name": "Centessa Pharmaceuticals PLC ADR", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "FMR LLC reports 1,800 Centessa shares (NASDAQ: CNTA)", "summary": "FMR LLC has filed an Amendment No. 4 to Schedule 13G/A, reporting beneficial ownership of 1,800 shares of Centessa Pharmaceuticals plc (NASDAQ: CNTA) common stock. This represents 0.0% of the class and names Abigail P. Johnson in the cover responses. The filing details are admini", "url": "https://www.stocktitan.net/sec-filings/CNTA/schedule-13g-a-centessa-pharmaceuticals-plc-amended-passive-investmen-9b3e125d1a38.html", "source_name": "Stock Titan", "published_at": "2026-07-08T14:41:35", "published_display": "08 Jul 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[15-12G] Centessa Pharmaceuticals plc SEC Filing", "summary": "Centessa Pharmaceuticals plc has filed a Form 15-12G with the SEC, indicating the termination of its registration under Section 12(g) and suspension of its duty to file reports under Sections 13 and 15(d) of the Securities Exchange Act of 1934. The filing, dated July 6, 2026, was", "url": "https://www.stocktitan.net/sec-filings/CNTA/15-12g-centessa-pharmaceuticals-plc-sec-filing-81c9ddd546e7.html", "source_name": "Stock Titan", "published_at": "2026-07-06T13:40:39", "published_display": "06 Jul 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Centessa Pharmaceuticals PLC ADR \u2013 MUN:260", "summary": "This article provides financial data for Centessa Pharmaceuticals PLC ADR (MUN:260), specifically focusing on its Enterprise Value to EBITDA forward metric. The data is sourced from TradingView and includes information from ICE Data Services and FactSet. The content is primarily ", "url": "https://www.tradingview.com/symbols/MUN-260/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T09:09:52", "published_display": "05 Jul 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Centessa Pharmaceuticals PLC ADR \u2013 MUN:260", "summary": "This article provides a brief snapshot of the \"Price to sales forward\" metric for Centessa Pharmaceuticals PLC ADR (MUN:260) on the Munich Stock Exchange. It likely presents current and historical values for this financial ratio. However, the core content provided is predominantl", "url": "https://www.tradingview.com/symbols/MUN-260/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T23:41:07", "published_display": "02 Jul 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Centessa Pharmaceuticals PLC ADR \u2013 MUN:260", "summary": "This article provides financial data for Centessa Pharmaceuticals PLC ADR (MUN:260), specifically focusing on its enterprise value to revenue forward. It appears to be a stub or a data-focused page from TradingView, indicating that the market is currently closed for this stock.", "url": "https://www.tradingview.com/symbols/MUN-260/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T05:41:43", "published_display": "02 Jul 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Centessa Pharmaceuticals PLC ADR \u2013 MUN:260", "summary": "The article focuses on the enterprise value to EBIT forward for Centessa Pharmaceuticals PLC ADR, traded under the symbol 260 on the Munich Stock Exchange. It provides a financial overview and notes that pricing data is provided by ICE Data Services and FactSet. The content is pr", "url": "https://www.tradingview.com/symbols/MUN-260/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T21:40:10", "published_display": "01 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Farallon Capital Management LLC Increases Stake in Centessa Phar", "summary": "Farallon Capital Management LLC has increased its stake in Centessa Pharmaceuticals PLC by adding over 4.5 million shares, bringing its total holdings to 9.37 million shares. This move signifies Farallon's confidence in the biotechnology sector and Centessa's innovative therapeut", "url": "https://www.gurufocus.com/news/8939816/farallon-capital-management-llc-increases-stake-in-centessa-pharmaceuticals-plc", "source_name": "GuruFocus", "published_at": "2026-07-01T01:39:16", "published_display": "01 Jul 2026 01:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Centessa Pharmaceuticals PLC ADR \u2013 MUN:260", "summary": "This article displays financial data for Centessa Pharmaceuticals PLC ADR (MUN:260), specifically focusing on its \"Price to book forward\" metric. The content provided is a data point without further analysis or context, suggesting it's part of a larger financial information platf", "url": "https://www.tradingview.com/symbols/MUN-260/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T06:09:29", "published_display": "30 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Centessa Pharmaceuticals PLC ADR \u2013 GETTEX:260", "summary": "The article displays the \"Price to book forward\" financial metric for Centessa Pharmaceuticals PLC ADR (GETTEX:260). It is a data page from TradingView, showing the absence of specific value, change, or percentage change for this metric, indicating that the data is either not ava", "url": "https://www.tradingview.com/symbols/GETTEX-260/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T05:40:29", "published_display": "29 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A Centessa Pharmaceuticals plc For: 26 June By Investing.com", "summary": "This article from Investing.com announces the filing of Form 13D/A for Centessa Pharmaceuticals plc, specifically mentioning a date of June 26. The main content of the article consists of various market data, news headlines, and navigational links common to financial news website", "url": "https://za.investing.com/news/stock-market-news/form-13da-centessa-pharmaceuticals-plc-for-26-june-93CH-4345850", "source_name": "Investing.com South Africa", "published_at": "2026-06-27T10:39:16", "published_display": "27 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "260 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a price target for Centessa Pharmaceuticals PLC ADR (260) on the Frankfurt Stock Exchange. Three analysts have provided a 1-year price forecast with a target of 37.52, though specific maximum and minimum estimates were not available. The information is not in", "url": "https://www.tradingview.com/symbols/FWB-260/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T21:11:16", "published_display": "26 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Centessa Pharmaceuticals (CNTA) holders exit after Eli Lilly acquisition closes", "summary": "Farallon Capital Management has fully divested its stake in Centessa Pharmaceuticals (CNTA) following the acquisition of Centessa by Eli Lilly and Company. Farallon filed an Amendment No. 1 to its Schedule 13D, reporting 0 beneficial ownership of Centessa ordinary shares as of Ju", "url": "https://www.stocktitan.net/sec-filings/CNTA/schedule-13d-a-centessa-pharmaceuticals-plc-amended-major-shareholder-8b3c0c1320bf.html", "source_name": "Stock Titan", "published_at": "2026-06-26T13:10:24", "published_display": "26 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders", "summary": "Eli Lilly and Company has successfully acquired Centessa Pharmaceuticals, a clinical-stage company specializing in treatments for sleep-wake disorders. This acquisition aims to advance therapies for conditions like narcolepsy by leveraging Centessa's portfolio of orexin receptor ", "url": "https://investingnews.com/lilly-completes-acquisition-of-centessa-pharmaceuticals-to-advance-treatments-for-sleep-wake-disorders/", "source_name": "Investing News Network", "published_at": "2026-06-25T20:10:24", "published_display": "25 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Centessa (CNTA) CAO cashed out as Eli Lilly acquires all shares", "summary": "Centessa Pharmaceuticals' Chief Accounting Officer, Raphael Deferiere, reported the automatic disposition of all his equity holdings, including 11,000 Ordinary Shares and options for 207,000 additional shares, as Eli Lilly completed its acquisition of Centessa via a UK Scheme of ", "url": "https://www.stocktitan.net/sec-filings/CNTA/form-4-centessa-pharmaceuticals-plc-insider-trading-activity-59841c2aa808.html", "source_name": "Stock Titan", "published_at": "2026-06-25T09:10:32", "published_display": "25 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eli Lilly Completes Acquisition of Centessa Pharmaceuticals to Advance Narcolepsy Treatments", "summary": "Eli Lilly and Company has completed its acquisition of Centessa Pharmaceuticals, aiming to advance narcolepsy treatments through Centessa's clinical-stage orexin receptor 2 agonists. This acquisition integrates Centessa's expertise and clinical portfolio into Lilly's neuroscience", "url": "https://sleepreviewmag.com/sleep-treatments/pharmaceuticals/emerging-compounds/eli-lilly-completes-acquisition-centessa-pharmaceuticals/", "source_name": "Sleep Review", "published_at": "2026-06-24T22:40:19", "published_display": "24 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Index Ventures entities exit Centessa (CNTA) stake as Eli Lilly acquisition closes", "summary": "Entities associated with Index Ventures have fully divested their 9,961,789 Ordinary Shares in Centessa Pharmaceuticals (CNTA). This transfer was an automatic consequence of Eli Lilly and Company's acquisition of Centessa, completed via a UK Scheme of Arrangement. Shareholders re", "url": "https://www.stocktitan.net/sec-filings/CNTA/form-4-centessa-pharmaceuticals-plc-insider-trading-activity-08f893b0d2d9.html", "source_name": "Stock Titan", "published_at": "2026-06-24T22:10:31", "published_display": "24 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eli Lilly acquisition cancels Centessa (NASDAQ: CNTA) director stock options for cash and CVRs", "summary": "Centessa Pharmaceuticals plc director Mary Lynne Hedley's stock options were cancelled and converted into cash and Contingent Value Rights (CVRs) as part of Eli Lilly's acquisition of Centessa on June 24, 2026. Option holders will receive $38.00 per share in cash, minus the exerc", "url": "https://www.stocktitan.net/sec-filings/CNTA/form-4-centessa-pharmaceuticals-plc-insider-trading-activity-cf38ad911f8e.html", "source_name": "Stock Titan", "published_at": "2026-06-24T20:40:20", "published_display": "24 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eli Lilly acquisition converts Centessa (NASDAQ: CNTA) director options into $38 cash plus CVRs", "summary": "Eli Lilly's acquisition of Centessa Pharmaceuticals resulted in the cancellation of Centessa director Carol Stuckley's share options. These options were converted into a right to receive $38.00 in cash per underlying share, plus one contingent value right (CVR) per share, offerin", "url": "https://www.stocktitan.net/sec-filings/CNTA/form-4-centessa-pharmaceuticals-plc-insider-trading-activity-ba429e6477e2.html", "source_name": "Stock Titan", "published_at": "2026-06-24T20:40:20", "published_display": "24 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lilly acquisition cashes out Centessa Pharmaceuticals (CNTA) officer equity", "summary": "Centessa Pharmaceuticals' Chief People Officer, Karen M. Anderson, reported the automatic disposition of all her equity holdings in connection with Eli Lilly's acquisition of the company. This included the transfer of Ordinary Shares, the vesting and cancellation of unvested Rest", "url": "https://www.stocktitan.net/sec-filings/CNTA/form-4-centessa-pharmaceuticals-plc-insider-trading-activity-30b39c1ef6ec.html", "source_name": "Stock Titan", "published_at": "2026-06-24T20:40:20", "published_display": "24 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eli Lilly deal cancels Centessa Pharmaceuticals (CNTA) director share options", "summary": "Centessa Pharmaceuticals director Samarth Kulkarni's share options were canceled as part of Eli Lilly and Company's acquisition of Centessa. All outstanding options were converted into a cash payment of $38.00 per underlying ordinary share minus the exercise price, plus one non-t", "url": "https://www.stocktitan.net/sec-filings/CNTA/form-4-centessa-pharmaceuticals-plc-insider-trading-activity-311938b29234.html", "source_name": "Stock Titan", "published_at": "2026-06-24T20:40:20", "published_display": "24 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eli Lilly buys Centessa (NASDAQ: CNTA) as director options convert to cash and CVRs", "summary": "Eli Lilly has completed its acquisition of Centessa Pharmaceuticals (NASDAQ: CNTA) via a UK scheme of arrangement, effective June 24, 2026. As part of the acquisition, Centessa director Dr. Brett Zbar's share options were cancelled and converted into cash payments based on an exc", "url": "https://www.stocktitan.net/sec-filings/CNTA/form-4-centessa-pharmaceuticals-plc-insider-trading-activity-8562729d2196.html", "source_name": "Stock Titan", "published_at": "2026-06-24T20:40:20", "published_display": "24 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Centessa Pharmaceuticals plc Insider Trading Activity", "summary": "This Form 4 filing details disposition transactions by Mathias Hukkelhoven, a director at Centessa Pharmaceuticals plc (CNTA). Following the acquisition of Centessa by Eli Lilly and Company, Hukkelhoven's share option awards were cancelled and converted into a cash payment of $38", "url": "https://www.stocktitan.net/sec-filings/CNTA/form-4-centessa-pharmaceuticals-plc-insider-trading-activity-9e3ca8760c97.html", "source_name": "Stock Titan", "published_at": "2026-06-24T20:40:19", "published_display": "24 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Centessa Pharmaceuticals (CNTA) Nasdaq ADSs Withdrawn from Listing", "summary": "Centessa Pharmaceuticals plc has notified Nasdaq of the removal of its American Depositary Shares (ADSs) from listing and registration on the Nasdaq Stock Market LLC. This withdrawal follows compliance by both the Exchange and the issuer with Nasdaq rules governing voluntary with", "url": "https://www.stocktitan.net/sec-filings/CNTA/25-nse-centessa-pharmaceuticals-plc-sec-filing-fb48efc86d52.html", "source_name": "Stock Titan", "published_at": "2026-06-24T14:11:01", "published_display": "24 Jun 2026 14:11", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lilly closes Centessa deal to pursue narcolepsy and sleep-wake drugs", "summary": "Eli Lilly (NYSE: LLY) has officially completed its acquisition of Centessa Pharmaceuticals, enhancing its pipeline with clinical-stage orexin receptor 2 agonists.", "url": "https://www.stocktitan.net/news/LLY/lilly-completes-acquisition-of-centessa-pharmaceuticals-to-advance-vb0viw04zzuk.html", "source_name": "Stock Titan", "published_at": "2026-06-24T13:11:38", "published_display": "24 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Centessa Pharmaceuticals Announced Transfer or Voluntary Withdrawal of Listing", "summary": "Centessa Pharmaceuticals announced it requested Nasdaq to halt trading of its ADSs and delist them following its acquisition by Lilly. The company plans to file a Form 15 to deregister its ADSs and suspend SEC reporting obligations after the Form 25 becomes effective. This news f", "url": "https://www.tradingview.com/news/tradingview:a47bf0282b1c9:0-centessa-pharmaceuticals-announced-transfer-or-voluntary-withdrawal-of-listing/", "source_name": "TradingView", "published_at": "2026-06-24T13:11:01", "published_display": "24 Jun 2026 13:11", "sentiment": "negative", "sentiment_pct": 15, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Centessa Pharmaceuticals Terminates Oxford Finance Loan After Closing of Lilly Acquisition", "summary": "Centessa Pharmaceuticals has terminated its Loan and Security Agreement with Oxford Finance and other lenders, effective June 24, 2026. This action follows the completion of its acquisition by Eli Lilly, with all indebtedness and obligations under the agreement having been fully ", "url": "https://www.tradingview.com/news/tradingview:7944136e8b4bd:0-centessa-pharmaceuticals-terminates-oxford-finance-loan-after-closing-of-lilly-acquisition/", "source_name": "TradingView", "published_at": "2026-06-24T13:11:00", "published_display": "24 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Centessa (NASDAQ: CNTA) bought by Eli Lilly for $38 plus CVR", "summary": "Eli Lilly has completed its acquisition of Centessa Pharmaceuticals plc for $38.00 in cash per share, plus one non-transferable contingent value right (CVR) that could provide up to an additional $9.00 per share based on milestone achievements. Centessa's ADSs have been halted on", "url": "https://www.stocktitan.net/sec-filings/CNTA/8-k-centessa-pharmaceuticals-plc-reports-material-event-eda79cbd28d3.html", "source_name": "Stock Titan", "published_at": "2026-06-24T13:11:00", "published_display": "24 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eli Lilly acquires Centessa (NASDAQ: CNTA) with $38 cash plus CVR per share", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPcmNXS3dqVjYzUHhfQzhBd2lOMGxqNjB1M1FXYW55cVRnYUhsU253cFFObXd1djRMbkZTQk9zVEFpT3h3N2JrMUJRV1l2T01qMmRaX3B1UEFqQTZESkxua1IxYV9UNHAxNVpFM0pzRmg2TDVDZzVwT1JSbmppTlFibmdkR0l6ZFk5Rl9ZaFNYM18xM2VITUI5MmhnUW1uMjBuR0NyNmd6Q0ZoMDl3YUlJdlVGMUhBYndtUDJTV0N1cw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Centessa (CNTA) sale to Eli Lilly at $38 plus CVR detailed in Form 4", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOZzFoaUJQX0VPRklKRU1IbFhJclYwMGk3VEJhakloQklpQWlmUE1TUnJvWHVNNWN3VmFJMVhRY3VpWWM2b0NoVlVqLWJqT05YNFdGcTFhOGNiSEpWN3pENXZBUUI4cEU2MjdIS19QZWRLYmhwNkJPcExqWXpmQ1dvTXBkM1BDSjZmVnh5U0EtMDlKS29OYTlhbjNjWXhLNm52Zk1lZV82SjdMT2hHRXJPb3dGbEFvN0dFb2djVWhzOA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Centessa (NASDAQ: CNTA) CEO\u2019s shares and options canceled in Eli Lilly cash-and-CVR deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPekUweG1jS29OY2k2bk1QWEpDWEphY054bThSZXN2eUd4MEhpaEtNWUI0ajZ2MVp6SFlqc2UtWlhnNTVqOGhadFBtaFV5UEdsNF9YbnVQYkxUeTR5WC1iNlhNb0R6eEFIVTRwMnlNUjFXM2hrb1JVRFdjeWxKbF85SklpTXpqNVFobmR5MTYyaERqNUtoXzlPZjFjVWQzT2hxaGFRX2tudTIxc291anZQd3lCYlpReVFQS0MyeERYMA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eli Lilly deal cashes out Centessa (CNTA) CMO\u2019s entire equity stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQalpVR2pZSmJCNzZNVlJHMkNjMXhIdlQwVkE0TjlJc000b25RWjBqUV8xRFh2ckhwVThjcU5DNV9KWmtYQ3NrdXNhZmRaclVVVDYzTHdWamRLSUZlZW15TllGR0F5ZThORnptTWxYWkVLTDdVYUhaY1JQQzhWemF1SlQ2OXlMV0ZXN1JLV3VlSnk1SzVNNnQzcFpuSDhvbG9RQWIxN0pPTmtPVmlwY3dySHNoZTI5SGVkRFQ2ZnRPMA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eli Lilly buys Centessa (CNTA); CFO shares and options canceled", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNYkI5NlJQX1V4ZUYyY3FQQ1ZuaHh5V1JFU2lzbWhzNXlrb3VXakdTWV8xQmhja3RmaHZyNjVLUW1ENm1OM3kwTHVKMGMwVm9nbXZnUG5ZU2sxdkpoZFdHeE83Z3F3ek5LS0NUQ1RJUzlRRlFZNE9NVV92TEh5SDZwRklud3c3ekRCampqOGlBckNBODVQMkZfYzg1eHc4Tmp6MThaSVNRSnVNOEFIX1gtdm5Wcm9uTTlmQXU2VXdJdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Centessa Pharmaceuticals (CNTA) holders get $38 cash plus CVR in Eli Lilly buyout", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOQzAxbWRYUnltNGJHajNDeWFteS1TbHJERFZkb3d4WmRfaHpKdG1tR1FPdXhQOWJuNVdmb1N3NDZKZDlTcS02Y2Q1cEFuMWF6b05jZUVCekhuWDBzMVBFUUppOVhRREJxMjgtcWhhZ3hMTWVnczJsa3Jjc0VKQjlRMFdBb1pjWmQwekRLVUJ5aERGbWw1bUxYNVQxXzRadmpDbGNhcjlhZ1RZUFN2VjB6VXE2RE1WUm11aEdrdVVfWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Farallon discloses 6.1% Centessa (NASDAQ: CNTA) ownership stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNOU5PVkZLSlNiRHcwWDdsTW5IelR0eDBxdmRWMS1fVkpQcVpjZDVwNmg5YzhIQllzU2dxaUNwaThrdG1MckRiSThDTy1vUDdfWkVhUS1CQWt0V0xxbE44RjRBQ0pzY3NZSVJxamlrbUQxaGszVjAwRnBvWk9KTlZ5RUN4MlZOeE5nUVBEOWYyVTl4QzZJSUs0ZnJQTTEyOFZ2SlZPZHBBbm0wTlc2bHRZOVMzdjlFQTZtY0tQbkg3ZGNwUkd5Y2gwVFlNOA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[POSASR] Centessa Pharmaceuticals plc SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNYTB1TmFYTUNza015MVZNUGp4QlpXMXR2aW5jWmF4RXZBM3pSQlNnOVFLZ0wzM0YwaTU1RGtiZ2dsSDNPMkEyakZYeG1ER0kyWjd1X2lKMzNDOHFjY1owQTN0b2tpMUNzampNZm0wVWRweHl2eUVuN3lGU1BSU3V2dURCWlFsTDBlcjJCdGtnUm1YY0VnSi1OUWpwLU9veDFQbXVycm9XcFpCVmRj?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is It Too Late To Consider Centessa Pharmaceuticals (CNTA) After A 191% One Year Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNYXVSMlhkdHk5c0FfM3g3cU5tSnhWeUloazJPQ29fckhwT2h4eXdoSXhWb05GQklnNnkzWkRDTVVXUzRaNXNrMF9SN2RKWTduYlNoeVZUY05neU5UV1Vuem1EV2tRamtQeUZhbVpSSkstNVEwOVdWeTRLTlB5dVZqSjduWldDb21xSjVfLWVzQzVDbERoOVJFNzVfV2I3NEZXN2JXcWNpTFZYc1U?oc=5", "source_name": "Market source", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "LLY to Buy Neuroscience Biotech Centessa Pharmaceuticals in $7.8B Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQeEZsSWp4dzEtUXZ1S3hVdldjZG13MmtsbHUtRmUwcHpjclZ4TFpWQ216RkxPM2hiTUFidk14ZVc4SkZEUVMxYmNjamNCU1V4d0h4eTBxeUVQa3BHXzlIQWQwTHB1dkE0Rkk1ZEJHaEcwYWhZcGtCeHVKOVhIZDgzUmhucWQ2Ul9KYjJoVWJnSVpjbGRGSmh2bzNudGVhcjc0TTdJN0JHcUxQdw?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "FMR LLC reports 1,800 Centessa shares (NASDAQ: CNTA)", "summary": "FMR LLC has filed an Amendment No. 4 to Schedule 13G/A, reporting beneficial ownership of 1,800 shares of Centessa Pharmaceuticals plc (NASDAQ: CNTA) common stock. This represents 0.0% of the class and names Abigail P. Johnson in the cover responses. The filing details are admini", "url": "https://www.stocktitan.net/sec-filings/CNTA/schedule-13g-a-centessa-pharmaceuticals-plc-amended-passive-investmen-9b3e125d1a38.html", "source_name": "Stock Titan", "published_at": "2026-07-08T14:41:35", "published_display": "08 Jul 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[15-12G] Centessa Pharmaceuticals plc SEC Filing", "summary": "Centessa Pharmaceuticals plc has filed a Form 15-12G with the SEC, indicating the termination of its registration under Section 12(g) and suspension of its duty to file reports under Sections 13 and 15(d) of the Securities Exchange Act of 1934. The filing, dated July 6, 2026, was", "url": "https://www.stocktitan.net/sec-filings/CNTA/15-12g-centessa-pharmaceuticals-plc-sec-filing-81c9ddd546e7.html", "source_name": "Stock Titan", "published_at": "2026-07-06T13:40:39", "published_display": "06 Jul 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Centessa Pharmaceuticals PLC ADR \u2013 MUN:260", "summary": "This article provides financial data for Centessa Pharmaceuticals PLC ADR (MUN:260), specifically focusing on its Enterprise Value to EBITDA forward metric. The data is sourced from TradingView and includes information from ICE Data Services and FactSet. The content is primarily ", "url": "https://www.tradingview.com/symbols/MUN-260/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T09:09:52", "published_display": "05 Jul 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Centessa Pharmaceuticals PLC ADR \u2013 MUN:260", "summary": "This article provides a brief snapshot of the \"Price to sales forward\" metric for Centessa Pharmaceuticals PLC ADR (MUN:260) on the Munich Stock Exchange. It likely presents current and historical values for this financial ratio. However, the core content provided is predominantl", "url": "https://www.tradingview.com/symbols/MUN-260/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T23:41:07", "published_display": "02 Jul 2026 23:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Centessa Pharmaceuticals PLC ADR \u2013 MUN:260", "summary": "This article provides financial data for Centessa Pharmaceuticals PLC ADR (MUN:260), specifically focusing on its enterprise value to revenue forward. It appears to be a stub or a data-focused page from TradingView, indicating that the market is currently closed for this stock.", "url": "https://www.tradingview.com/symbols/MUN-260/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T05:41:43", "published_display": "02 Jul 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Centessa Pharmaceuticals PLC ADR \u2013 MUN:260", "summary": "The article focuses on the enterprise value to EBIT forward for Centessa Pharmaceuticals PLC ADR, traded under the symbol 260 on the Munich Stock Exchange. It provides a financial overview and notes that pricing data is provided by ICE Data Services and FactSet. The content is pr", "url": "https://www.tradingview.com/symbols/MUN-260/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T21:40:10", "published_display": "01 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Farallon Capital Management LLC Increases Stake in Centessa Phar", "summary": "Farallon Capital Management LLC has increased its stake in Centessa Pharmaceuticals PLC by adding over 4.5 million shares, bringing its total holdings to 9.37 million shares. This move signifies Farallon's confidence in the biotechnology sector and Centessa's innovative therapeut", "url": "https://www.gurufocus.com/news/8939816/farallon-capital-management-llc-increases-stake-in-centessa-pharmaceuticals-plc", "source_name": "GuruFocus", "published_at": "2026-07-01T01:39:16", "published_display": "01 Jul 2026 01:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Centessa Pharmaceuticals PLC ADR \u2013 MUN:260", "summary": "This article displays financial data for Centessa Pharmaceuticals PLC ADR (MUN:260), specifically focusing on its \"Price to book forward\" metric. The content provided is a data point without further analysis or context, suggesting it's part of a larger financial information platf", "url": "https://www.tradingview.com/symbols/MUN-260/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T06:09:29", "published_display": "30 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Centessa Pharmaceuticals PLC ADR \u2013 GETTEX:260", "summary": "The article displays the \"Price to book forward\" financial metric for Centessa Pharmaceuticals PLC ADR (GETTEX:260). It is a data page from TradingView, showing the absence of specific value, change, or percentage change for this metric, indicating that the data is either not ava", "url": "https://www.tradingview.com/symbols/GETTEX-260/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T05:40:29", "published_display": "29 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A Centessa Pharmaceuticals plc For: 26 June By Investing.com", "summary": "This article from Investing.com announces the filing of Form 13D/A for Centessa Pharmaceuticals plc, specifically mentioning a date of June 26. The main content of the article consists of various market data, news headlines, and navigational links common to financial news website", "url": "https://za.investing.com/news/stock-market-news/form-13da-centessa-pharmaceuticals-plc-for-26-june-93CH-4345850", "source_name": "Investing.com South Africa", "published_at": "2026-06-27T10:39:16", "published_display": "27 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "260 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a price target for Centessa Pharmaceuticals PLC ADR (260) on the Frankfurt Stock Exchange. Three analysts have provided a 1-year price forecast with a target of 37.52, though specific maximum and minimum estimates were not available. The information is not in", "url": "https://www.tradingview.com/symbols/FWB-260/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T21:11:16", "published_display": "26 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Centessa Pharmaceuticals (CNTA) holders exit after Eli Lilly acquisition closes", "summary": "Farallon Capital Management has fully divested its stake in Centessa Pharmaceuticals (CNTA) following the acquisition of Centessa by Eli Lilly and Company. Farallon filed an Amendment No. 1 to its Schedule 13D, reporting 0 beneficial ownership of Centessa ordinary shares as of Ju", "url": "https://www.stocktitan.net/sec-filings/CNTA/schedule-13d-a-centessa-pharmaceuticals-plc-amended-major-shareholder-8b3c0c1320bf.html", "source_name": "Stock Titan", "published_at": "2026-06-26T13:10:24", "published_display": "26 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders", "summary": "Eli Lilly and Company has successfully acquired Centessa Pharmaceuticals, a clinical-stage company specializing in treatments for sleep-wake disorders. This acquisition aims to advance therapies for conditions like narcolepsy by leveraging Centessa's portfolio of orexin receptor ", "url": "https://investingnews.com/lilly-completes-acquisition-of-centessa-pharmaceuticals-to-advance-treatments-for-sleep-wake-disorders/", "source_name": "Investing News Network", "published_at": "2026-06-25T20:10:24", "published_display": "25 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Centessa (CNTA) CAO cashed out as Eli Lilly acquires all shares", "summary": "Centessa Pharmaceuticals' Chief Accounting Officer, Raphael Deferiere, reported the automatic disposition of all his equity holdings, including 11,000 Ordinary Shares and options for 207,000 additional shares, as Eli Lilly completed its acquisition of Centessa via a UK Scheme of ", "url": "https://www.stocktitan.net/sec-filings/CNTA/form-4-centessa-pharmaceuticals-plc-insider-trading-activity-59841c2aa808.html", "source_name": "Stock Titan", "published_at": "2026-06-25T09:10:32", "published_display": "25 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eli Lilly Completes Acquisition of Centessa Pharmaceuticals to Advance Narcolepsy Treatments", "summary": "Eli Lilly and Company has completed its acquisition of Centessa Pharmaceuticals, aiming to advance narcolepsy treatments through Centessa's clinical-stage orexin receptor 2 agonists. This acquisition integrates Centessa's expertise and clinical portfolio into Lilly's neuroscience", "url": "https://sleepreviewmag.com/sleep-treatments/pharmaceuticals/emerging-compounds/eli-lilly-completes-acquisition-centessa-pharmaceuticals/", "source_name": "Sleep Review", "published_at": "2026-06-24T22:40:19", "published_display": "24 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Index Ventures entities exit Centessa (CNTA) stake as Eli Lilly acquisition closes", "summary": "Entities associated with Index Ventures have fully divested their 9,961,789 Ordinary Shares in Centessa Pharmaceuticals (CNTA). This transfer was an automatic consequence of Eli Lilly and Company's acquisition of Centessa, completed via a UK Scheme of Arrangement. Shareholders re", "url": "https://www.stocktitan.net/sec-filings/CNTA/form-4-centessa-pharmaceuticals-plc-insider-trading-activity-08f893b0d2d9.html", "source_name": "Stock Titan", "published_at": "2026-06-24T22:10:31", "published_display": "24 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eli Lilly acquisition cancels Centessa (NASDAQ: CNTA) director stock options for cash and CVRs", "summary": "Centessa Pharmaceuticals plc director Mary Lynne Hedley's stock options were cancelled and converted into cash and Contingent Value Rights (CVRs) as part of Eli Lilly's acquisition of Centessa on June 24, 2026. Option holders will receive $38.00 per share in cash, minus the exerc", "url": "https://www.stocktitan.net/sec-filings/CNTA/form-4-centessa-pharmaceuticals-plc-insider-trading-activity-cf38ad911f8e.html", "source_name": "Stock Titan", "published_at": "2026-06-24T20:40:20", "published_display": "24 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eli Lilly acquisition converts Centessa (NASDAQ: CNTA) director options into $38 cash plus CVRs", "summary": "Eli Lilly's acquisition of Centessa Pharmaceuticals resulted in the cancellation of Centessa director Carol Stuckley's share options. These options were converted into a right to receive $38.00 in cash per underlying share, plus one contingent value right (CVR) per share, offerin", "url": "https://www.stocktitan.net/sec-filings/CNTA/form-4-centessa-pharmaceuticals-plc-insider-trading-activity-ba429e6477e2.html", "source_name": "Stock Titan", "published_at": "2026-06-24T20:40:20", "published_display": "24 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lilly acquisition cashes out Centessa Pharmaceuticals (CNTA) officer equity", "summary": "Centessa Pharmaceuticals' Chief People Officer, Karen M. Anderson, reported the automatic disposition of all her equity holdings in connection with Eli Lilly's acquisition of the company. This included the transfer of Ordinary Shares, the vesting and cancellation of unvested Rest", "url": "https://www.stocktitan.net/sec-filings/CNTA/form-4-centessa-pharmaceuticals-plc-insider-trading-activity-30b39c1ef6ec.html", "source_name": "Stock Titan", "published_at": "2026-06-24T20:40:20", "published_display": "24 Jun 2026 20:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eli Lilly deal cancels Centessa Pharmaceuticals (CNTA) director share options", "summary": "Centessa Pharmaceuticals director Samarth Kulkarni's share options were canceled as part of Eli Lilly and Company's acquisition of Centessa. All outstanding options were converted into a cash payment of $38.00 per underlying ordinary share minus the exercise price, plus one non-t", "url": "https://www.stocktitan.net/sec-filings/CNTA/form-4-centessa-pharmaceuticals-plc-insider-trading-activity-311938b29234.html", "source_name": "Stock Titan", "published_at": "2026-06-24T20:40:20", "published_display": "24 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eli Lilly buys Centessa (NASDAQ: CNTA) as director options convert to cash and CVRs", "summary": "Eli Lilly has completed its acquisition of Centessa Pharmaceuticals (NASDAQ: CNTA) via a UK scheme of arrangement, effective June 24, 2026. As part of the acquisition, Centessa director Dr. Brett Zbar's share options were cancelled and converted into cash payments based on an exc", "url": "https://www.stocktitan.net/sec-filings/CNTA/form-4-centessa-pharmaceuticals-plc-insider-trading-activity-8562729d2196.html", "source_name": "Stock Titan", "published_at": "2026-06-24T20:40:20", "published_display": "24 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Centessa Pharmaceuticals plc Insider Trading Activity", "summary": "This Form 4 filing details disposition transactions by Mathias Hukkelhoven, a director at Centessa Pharmaceuticals plc (CNTA). Following the acquisition of Centessa by Eli Lilly and Company, Hukkelhoven's share option awards were cancelled and converted into a cash payment of $38", "url": "https://www.stocktitan.net/sec-filings/CNTA/form-4-centessa-pharmaceuticals-plc-insider-trading-activity-9e3ca8760c97.html", "source_name": "Stock Titan", "published_at": "2026-06-24T20:40:19", "published_display": "24 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Centessa Pharmaceuticals (CNTA) Nasdaq ADSs Withdrawn from Listing", "summary": "Centessa Pharmaceuticals plc has notified Nasdaq of the removal of its American Depositary Shares (ADSs) from listing and registration on the Nasdaq Stock Market LLC. This withdrawal follows compliance by both the Exchange and the issuer with Nasdaq rules governing voluntary with", "url": "https://www.stocktitan.net/sec-filings/CNTA/25-nse-centessa-pharmaceuticals-plc-sec-filing-fb48efc86d52.html", "source_name": "Stock Titan", "published_at": "2026-06-24T14:11:01", "published_display": "24 Jun 2026 14:11", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lilly closes Centessa deal to pursue narcolepsy and sleep-wake drugs", "summary": "Eli Lilly (NYSE: LLY) has officially completed its acquisition of Centessa Pharmaceuticals, enhancing its pipeline with clinical-stage orexin receptor 2 agonists.", "url": "https://www.stocktitan.net/news/LLY/lilly-completes-acquisition-of-centessa-pharmaceuticals-to-advance-vb0viw04zzuk.html", "source_name": "Stock Titan", "published_at": "2026-06-24T13:11:38", "published_display": "24 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Centessa Pharmaceuticals Announced Transfer or Voluntary Withdrawal of Listing", "summary": "Centessa Pharmaceuticals announced it requested Nasdaq to halt trading of its ADSs and delist them following its acquisition by Lilly. The company plans to file a Form 15 to deregister its ADSs and suspend SEC reporting obligations after the Form 25 becomes effective. This news f", "url": "https://www.tradingview.com/news/tradingview:a47bf0282b1c9:0-centessa-pharmaceuticals-announced-transfer-or-voluntary-withdrawal-of-listing/", "source_name": "TradingView", "published_at": "2026-06-24T13:11:01", "published_display": "24 Jun 2026 13:11", "sentiment": "negative", "sentiment_pct": 15, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Centessa Pharmaceuticals Terminates Oxford Finance Loan After Closing of Lilly Acquisition", "summary": "Centessa Pharmaceuticals has terminated its Loan and Security Agreement with Oxford Finance and other lenders, effective June 24, 2026. This action follows the completion of its acquisition by Eli Lilly, with all indebtedness and obligations under the agreement having been fully ", "url": "https://www.tradingview.com/news/tradingview:7944136e8b4bd:0-centessa-pharmaceuticals-terminates-oxford-finance-loan-after-closing-of-lilly-acquisition/", "source_name": "TradingView", "published_at": "2026-06-24T13:11:00", "published_display": "24 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Centessa (NASDAQ: CNTA) bought by Eli Lilly for $38 plus CVR", "summary": "Eli Lilly has completed its acquisition of Centessa Pharmaceuticals plc for $38.00 in cash per share, plus one non-transferable contingent value right (CVR) that could provide up to an additional $9.00 per share based on milestone achievements. Centessa's ADSs have been halted on", "url": "https://www.stocktitan.net/sec-filings/CNTA/8-k-centessa-pharmaceuticals-plc-reports-material-event-eda79cbd28d3.html", "source_name": "Stock Titan", "published_at": "2026-06-24T13:11:00", "published_display": "24 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eli Lilly acquires Centessa (NASDAQ: CNTA) with $38 cash plus CVR per share", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPcmNXS3dqVjYzUHhfQzhBd2lOMGxqNjB1M1FXYW55cVRnYUhsU253cFFObXd1djRMbkZTQk9zVEFpT3h3N2JrMUJRV1l2T01qMmRaX3B1UEFqQTZESkxua1IxYV9UNHAxNVpFM0pzRmg2TDVDZzVwT1JSbmppTlFibmdkR0l6ZFk5Rl9ZaFNYM18xM2VITUI5MmhnUW1uMjBuR0NyNmd6Q0ZoMDl3YUlJdlVGMUhBYndtUDJTV0N1cw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Centessa (CNTA) sale to Eli Lilly at $38 plus CVR detailed in Form 4", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOZzFoaUJQX0VPRklKRU1IbFhJclYwMGk3VEJhakloQklpQWlmUE1TUnJvWHVNNWN3VmFJMVhRY3VpWWM2b0NoVlVqLWJqT05YNFdGcTFhOGNiSEpWN3pENXZBUUI4cEU2MjdIS19QZWRLYmhwNkJPcExqWXpmQ1dvTXBkM1BDSjZmVnh5U0EtMDlKS29OYTlhbjNjWXhLNm52Zk1lZV82SjdMT2hHRXJPb3dGbEFvN0dFb2djVWhzOA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Centessa (NASDAQ: CNTA) CEO\u2019s shares and options canceled in Eli Lilly cash-and-CVR deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPekUweG1jS29OY2k2bk1QWEpDWEphY054bThSZXN2eUd4MEhpaEtNWUI0ajZ2MVp6SFlqc2UtWlhnNTVqOGhadFBtaFV5UEdsNF9YbnVQYkxUeTR5WC1iNlhNb0R6eEFIVTRwMnlNUjFXM2hrb1JVRFdjeWxKbF85SklpTXpqNVFobmR5MTYyaERqNUtoXzlPZjFjVWQzT2hxaGFRX2tudTIxc291anZQd3lCYlpReVFQS0MyeERYMA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eli Lilly deal cashes out Centessa (CNTA) CMO\u2019s entire equity stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQalpVR2pZSmJCNzZNVlJHMkNjMXhIdlQwVkE0TjlJc000b25RWjBqUV8xRFh2ckhwVThjcU5DNV9KWmtYQ3NrdXNhZmRaclVVVDYzTHdWamRLSUZlZW15TllGR0F5ZThORnptTWxYWkVLTDdVYUhaY1JQQzhWemF1SlQ2OXlMV0ZXN1JLV3VlSnk1SzVNNnQzcFpuSDhvbG9RQWIxN0pPTmtPVmlwY3dySHNoZTI5SGVkRFQ2ZnRPMA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eli Lilly buys Centessa (CNTA); CFO shares and options canceled", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNYkI5NlJQX1V4ZUYyY3FQQ1ZuaHh5V1JFU2lzbWhzNXlrb3VXakdTWV8xQmhja3RmaHZyNjVLUW1ENm1OM3kwTHVKMGMwVm9nbXZnUG5ZU2sxdkpoZFdHeE83Z3F3ek5LS0NUQ1RJUzlRRlFZNE9NVV92TEh5SDZwRklud3c3ekRCampqOGlBckNBODVQMkZfYzg1eHc4Tmp6MThaSVNRSnVNOEFIX1gtdm5Wcm9uTTlmQXU2VXdJdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Centessa Pharmaceuticals (CNTA) holders get $38 cash plus CVR in Eli Lilly buyout", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOQzAxbWRYUnltNGJHajNDeWFteS1TbHJERFZkb3d4WmRfaHpKdG1tR1FPdXhQOWJuNVdmb1N3NDZKZDlTcS02Y2Q1cEFuMWF6b05jZUVCekhuWDBzMVBFUUppOVhRREJxMjgtcWhhZ3hMTWVnczJsa3Jjc0VKQjlRMFdBb1pjWmQwekRLVUJ5aERGbWw1bUxYNVQxXzRadmpDbGNhcjlhZ1RZUFN2VjB6VXE2RE1WUm11aEdrdVVfWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Farallon discloses 6.1% Centessa (NASDAQ: CNTA) ownership stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNOU5PVkZLSlNiRHcwWDdsTW5IelR0eDBxdmRWMS1fVkpQcVpjZDVwNmg5YzhIQllzU2dxaUNwaThrdG1MckRiSThDTy1vUDdfWkVhUS1CQWt0V0xxbE44RjRBQ0pzY3NZSVJxamlrbUQxaGszVjAwRnBvWk9KTlZ5RUN4MlZOeE5nUVBEOWYyVTl4QzZJSUs0ZnJQTTEyOFZ2SlZPZHBBbm0wTlc2bHRZOVMzdjlFQTZtY0tQbkg3ZGNwUkd5Y2gwVFlNOA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[POSASR] Centessa Pharmaceuticals plc SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNYTB1TmFYTUNza015MVZNUGp4QlpXMXR2aW5jWmF4RXZBM3pSQlNnOVFLZ0wzM0YwaTU1RGtiZ2dsSDNPMkEyakZYeG1ER0kyWjd1X2lKMzNDOHFjY1owQTN0b2tpMUNzampNZm0wVWRweHl2eUVuN3lGU1BSU3V2dURCWlFsTDBlcjJCdGtnUm1YY0VnSi1OUWpwLU9veDFQbXVycm9XcFpCVmRj?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Centessa Pharmaceuticals (CNTA) After A 191% One Year Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNYXVSMlhkdHk5c0FfM3g3cU5tSnhWeUloazJPQ29fckhwT2h4eXdoSXhWb05GQklnNnkzWkRDTVVXUzRaNXNrMF9SN2RKWTduYlNoeVZUY05neU5UV1Vuem1EV2tRamtQeUZhbVpSSkstNVEwOVdWeTRLTlB5dVZqSjduWldDb21xSjVfLWVzQzVDbERoOVJFNzVfV2I3NEZXN2JXcWNpTFZYc1U?oc=5", "source_name": "Market source", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LLY to Buy Neuroscience Biotech Centessa Pharmaceuticals in $7.8B Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQeEZsSWp4dzEtUXZ1S3hVdldjZG13MmtsbHUtRmUwcHpjclZ4TFpWQ216RkxPM2hiTUFidk14ZVc4SkZEUVMxYmNjamNCU1V4d0h4eTBxeUVQa3BHXzlIQWQwTHB1dkE0Rkk1ZEJHaEcwYWhZcGtCeHVKOVhIZDgzUmhucWQ2Ul9KYjJoVWJnSVpjbGRGSmh2bzNudGVhcjc0TTdJN0JHcUxQdw?oc=5", "source_name": "Market source", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 81, "total_relevant": 45, "sentiment_summary": {"positive": 8, "negative": 3, "neutral": 34, "score": 52, "total": 45, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "deals", "primary_label": "Deals and strategy", "confidence": 76, "events": [{"event": "deals", "label": "Deals and strategy", "weight": 11.0, "count": 20}, {"event": "general", "label": "Market update", "weight": 7.15, "count": 13}, {"event": "earnings", "label": "Earnings", "weight": 3.85, "count": 9}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 8, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 40.5, "latest_week": "2026-06-26", "one_week_move": 1.2, "four_week_move": 1.9, "twelve_week_move": 2.0, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.632827, "market_dynamics_buy_signal": false, "relative_strength": 33.197961, "fair_value_gap": 144.4, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 52.7262, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.2% over one week, +1.9% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 59, "badges": [], "opportunities": [], "risks": [], "event_label": "Deals and strategy", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 22}, {"label": "TradingView", "count": 10}, {"label": "Market source", "count": 7}, {"label": "simplywall.st", "count": 2}, {"label": "GuruFocus", "count": 1}, {"label": "Investing.com South Africa", "count": 1}, {"label": "Investing News Network", "count": 1}, {"label": "Sleep Review", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 37}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Deals and strategy", "count": 20}, {"label": "Market update", "count": 13}, {"label": "Earnings", "count": 9}, {"label": "Balance sheet", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Deals and strategy", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "37", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+1.2% over one week, +1.9% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "FMR LLC reports 1,800 Centessa shares (NASDAQ: CNTA)"}], "updated_at": "2026-07-16T08:10:41.075731+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}